Literature DB >> 21030484

Functional selectivity and biased receptor signaling.

Terry Kenakin1.   

Abstract

With the emergence of information describing functional selectivity and biased agonists and antagonists has come a lack of confidence in "one size fits all" assays for detection of agonism. Seven-transmembrane receptors are pleiotropic with respect to the signaling protein to which they couple in a cell, and many conformations of the receptor can be formed; this leads to systems where ligands can stabilize unique conformations that go on to selectively activate signaling pathways. Thus, such "biased" ligands can produce cell-specific agonism that may require targeted assays to detect and quantify. It also predicts that ligands can have many different efficacies for the many behaviors that the receptor can exhibit (referred to as "pluridimensional efficacy"), leading to a breakdown in the common classifications of agonist and antagonist. This all poses unique challenges to the pharmacologic nomenclature of drugs, the detection and optimization of new drugs, and the association of phenotypic clinical profiles with pharmacological properties of drugs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21030484     DOI: 10.1124/jpet.110.173948

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  189 in total

Review 1.  Targeting proteinase-activated receptors: therapeutic potential and challenges.

Authors:  Rithwik Ramachandran; Farshid Noorbakhsh; Kathryn Defea; Morley D Hollenberg
Journal:  Nat Rev Drug Discov       Date:  2012-01-03       Impact factor: 84.694

Review 2.  Biased signalling and allosteric machines: new vistas and challenges for drug discovery.

Authors:  Terry P Kenakin
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 3.  Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model.

Authors:  Clint E Canal; Drake Morgan
Journal:  Drug Test Anal       Date:  2012-04-19       Impact factor: 3.345

Review 4.  The significance of G protein-coupled receptor crystallography for drug discovery.

Authors:  John A Salon; David T Lodowski; Krzysztof Palczewski
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

Review 5.  Ligand-directed signalling within the opioid receptor family.

Authors:  Amynah A Pradhan; Monique L Smith; Brigitte L Kieffer; Christopher J Evans
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

Review 6.  Functional selectivity in GPCR heterocomplexes.

Authors:  J González-Maeso; S C Sealfon
Journal:  Mini Rev Med Chem       Date:  2012-08       Impact factor: 3.862

7.  Effects of β-blockers on house dust mite-driven murine models pre- and post-development of an asthma phenotype.

Authors:  Radhika Joshi; Daniel Valdez; Hosu Kim; Douglas C Eikenburg; Brian J Knoll; Richard A Bond
Journal:  Pulm Pharmacol Ther       Date:  2017-07-17       Impact factor: 3.410

Review 8.  Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.

Authors:  John T Williams; Susan L Ingram; Graeme Henderson; Charles Chavkin; Mark von Zastrow; Stefan Schulz; Thomas Koch; Christopher J Evans; Macdonald J Christie
Journal:  Pharmacol Rev       Date:  2013-01-15       Impact factor: 25.468

9.  A Genetically Encoded Biosensor Reveals Location Bias of Opioid Drug Action.

Authors:  Miriam Stoeber; Damien Jullié; Braden T Lobingier; Toon Laeremans; Jan Steyaert; Peter W Schiller; Aashish Manglik; Mark von Zastrow
Journal:  Neuron       Date:  2018-05-10       Impact factor: 17.173

10.  Estimation of ligand affinity constants for receptor states in functional studies involving the allosteric modulation of G protein-coupled receptors: implications for ligand bias.

Authors:  Frederick J Ehlert; Michael T Griffin
Journal:  J Pharmacol Toxicol Methods       Date:  2014-01-13       Impact factor: 1.950

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.